- Home
- LYRA vs SOAR Comparison
LYRA vs SOAR Comparison
Compare LYRA & SOAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- SOAR
- Stock Information
- Founded
- LYRA 2005
- SOAR 2021
- Country
- LYRA United States
- SOAR United States
- Employees
- LYRA N/A
- SOAR N/A
- Industry
- LYRA Medical/Dental Instruments
- SOAR Blank Checks
- Sector
- LYRA Health Care
- SOAR Finance
- Exchange
- LYRA Nasdaq
- SOAR Nasdaq
- Market Cap
- LYRA 11.3M
- SOAR 9.4M
- IPO Year
- LYRA 2020
- SOAR N/A
- Fundamental
- Price
- LYRA $6.85
- SOAR $1.51
- Analyst Decision
- LYRA Hold
- SOAR
- Analyst Count
- LYRA 1
- SOAR 0
- Target Price
- LYRA $16.00
- SOAR N/A
- AVG Volume (30 Days)
- LYRA 14.2K
- SOAR 969.4K
- Earning Date
- LYRA 08-12-2025
- SOAR 08-14-2025
- Dividend Yield
- LYRA N/A
- SOAR N/A
- EPS Growth
- LYRA N/A
- SOAR N/A
- EPS
- LYRA N/A
- SOAR N/A
- Revenue
- LYRA $770,000.00
- SOAR $96,397,000.00
- Revenue This Year
- LYRA N/A
- SOAR N/A
- Revenue Next Year
- LYRA $123.46
- SOAR N/A
- P/E Ratio
- LYRA N/A
- SOAR N/A
- Revenue Growth
- LYRA N/A
- SOAR 309.80
- 52 Week Low
- LYRA $3.81
- SOAR $1.14
- 52 Week High
- LYRA $37.50
- SOAR $19.06
- Technical
- Relative Strength Index (RSI)
- LYRA 42.34
- SOAR 46.70
- Support Level
- LYRA $6.91
- SOAR $1.57
- Resistance Level
- LYRA $7.50
- SOAR $1.75
- Average True Range (ATR)
- LYRA 0.33
- SOAR 0.14
- MACD
- LYRA 0.06
- SOAR -0.00
- Stochastic Oscillator
- LYRA 16.18
- SOAR 36.79
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.